Imbalance of Plasminogen Activator Inhibitor-I/ Tissue Plasminogen Activator and Tissue Factor/Tissue Factor Pathway Inhibitor in Young Japanese Men with Myocardial Infarction

Summary

To evaluate the association between haemostatic parameters and increased risk of myocardial infarction (MI) at a young age, we measured fibrinogen, factor VII, antithrombin III, protein C, protein S, tissue factor (TF), free form tissue factor pathway inhibitor (TFPI), plasminogen, ₂-antiplasmin, tissue plasminogen activator (tPA), plasminogen activator inhibitor-I (PAI-I), and lipoprotein (a) in 140 young men with MI before age 45 and 150 age-matched healthy men. TF, TF/TFPI ratio, PAI-I, PAI-I/tPA ratio, plasminogen, and lipoprotein (a) in young MI patients were all significantly higher than controls, while TFPI, antithrombin III, and tPA were significantly lower (P <0.001 of each). Significant determinants of MI risk were PAI-I/tPA ratio (R² = 0.300, P <0.001), TF/TFPI ratio (R² = 0.049, P <0.001), antithrombin III (R² = 0.034, P <0.001), hyperlipidaemia (R² = 0.019, P = 0.004), diabetes (R² = 0.014, P = 0.015), lipoprotein (a) (R² = 0.012, P = 0.023), ₂-antiplasmin (R² = 0.014, P = 0.012), and protein C (R² = 0.012, P = 0.018). We conclude that the imbalances of PAI-I/tPA and TF/TFPI are significantly associated with MI at a young age, perhaps mediated via impaired fibrinolytic activity.

Keywords

Myocardial infarction - age - risk factors - coagulation - fibrinolysis

• References

• 1 Choudhury L, Marsh JD. Myocardial infarction in young patients. Am J Med 1999; 107: 254-61.
• 2 Hamsten A, Walldius G, Szamosi A, Dahlen G, de Faire U. Relationship of angiographically defined coronary artery disease to serum lipoproteins and apolipoproteins in young survivors of myocardial infarction. Circulation 1986; 73: 1097-110.
• 3 Hoit BD, Gilpin EA, Henning H, Maisel AA, Dittrich H, Carlisle J, Ross Jr J. Myocardial infarction in young patients: An analysis by age subsets. Circulation 1986; 74: 712-21.
• 4 Barbash GI, White HD, Modan M, Diaz R, Hamptom JR, Heikkla J, Kristinsson A, Moulopolos S, Paolosso EAC, van der Werf T, Pehrsson K, Sandoe E, Simes J, Wilkox RG, Verstraete M, van der Lippe G, van der Werf F. Acute myocardial infarction in the young. – The role of smoking. The Investigators of The International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Eur Heart J 1995; 16: 313-6.
• 5 Zimmerman FH, Cameron A, Fisher LD, Grace NG. Myocardial infarction in young adults: Angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). J Am Coll Cardiol 1995; 26: 654-61.
• 6 Ogawa K, Numao T, Iizuka M, Yanagisawa A, Yoshino H, Ishikawa K, Miyake F, Matsumoto N, Murayama M, Hasegawa N, Kobayashi A, Kikawada R, Kinoshita S, Muramatsu T, Matsuo H, Isshiki T, Ochiai M, Miyashita H. Angiographic and coronary risk factor analyses of Japanese patients with ischemic heart disease before age 40. – A multicenter cooperative study. Jpn Circ J 1996; 60: 822-30.
• 7 Moccette T, Malacrida R, Pasotti E, Sessa F, Genoni M, Barlera S, Turazza F, Maggioni AP. Epidemiologic variables and outcome of 1972 young patients with acute myocardial infarction. Data from the GISSI-2 database. The GISSI investigators. Arch Intern Med 1997; 157: 865-9.
• 8 Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994; 330: 1041-6.
• 9 Davia JE, Hallal FJ, Cheitlin MD, Gregoratos G, Mccarty R, Foote W. Coronary artery disease in young patients: Arteriographic and clinical review of 40 cases aged 35 and under. Am Heart J 1974; 87: 689-96.
• 10 Raymond R, Lynch J, Underwood D, Leatherman J, Razavi M. Myocardial infarction and normal coronary arteriography: A 10 years clinical and risk analysis of 74 patients. J Am Coll Cardiol 1988; 11: 471-7.
• 11 Corrado D, Thiene G, Cocco P, Frescura C. Non-atherosclerotic coronary artery disease and sudden death in the young. Br Heart J 1992; 68: 601-7.
• 12 Meada TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
• 13 Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258: 1183-6.
• 14 Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191-205.
• 15 Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-63.
• 16 Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
• 17 Green D, Chamberlain MA, Ruth KJ, Folsom AR, Liu K. Factor VII cholesterol, and triglycerides. The CARDIA Study. Arterioscler Thromb Vasc Biol 1997; 17: 51-5.
• 18 Scarabin P-Y, Aillaud M-F, Amouyel P, Evans A, Luc G, Ferrières J, Arveiler D, Juhan-Vague I. Associations of fibrinogen, factor VII and PAI-I with baseline findings among 10,500 male participants in a prospective study of myocardial infarction. The Prime Study. Thromb Haemost 1998; 80: 749-56.
• 19 Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 2000; 133: 81-91.
• 20 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
• 21 Siscovick DS, Rosendaal SFR, Psaty BM. Thrombosis in the young: Effect of atherosclerotic risk factors on the risk of myocardial infarction associated with prothrombotic factors. Thromb Haemost 1997; 78: 7-12.
• 22 Harris EN, Charavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GRV. Anticardiolipin antibodies: Detection by radio-immunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211-4.
• 23 Bili A, Moss AJ, Francis CW, Zareba W, Watelet LFM, Sanz I. Anticardiolipin antibodies and recurrent coronary events. A prospective study of 1150 patients. Circulation 2000; 102: 1258-63.
• 24 Bux-Gewehr I, Nacke A, Feurle GE. Recurring myocardial infarction in a 35 year old woman. Heart 1999; 81: 316-7.
• 25 Sakata T, Kario K, Katayama Y, Matsuyama T, Kato H, Miyata T. Analysis of 45 episodes of arterial occlusive disease in Japanese patients with congenital protein C deficiency. Thromb Res 1999; 94: 69-78.
• 26 Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
• 27 Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-63.
• 28 Hamsten A, de Faire U, Walldius G, Dahlén G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-8.
• 29 Malmberg K, Båvenholm P, Hamsten A. Clinical and biochemical factors associated with prognosis after myocardial infarction at a young age. J Am Coll Cardiol 1994; 24: 592-9.
• 30 Båvenholm P, de Faire U, Landou C, Efendic S, Nilsson J, Wiman B, Hamsten A. Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function. Eur Heart J 1998; 19: 402-10.
• 31 Bara L, Nicaud V, Tiret L, Cambien F, Samama MM. Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIC and PAI-1 in European offspring. – The EARS Study. Thromb Haemost 1994; 71: 434-40.
• 32 Fatah K, Silveira A, Tornvall P, Karpe F, Blombäck M, Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76: 535-40.
• 33 Olofsson BO, Dahlén G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989; 10: 77-82.
• 34 Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94: 2057-63.
• 35 Held C, Hjemdahl P, Rehnqvist N, Wallén NH, Björkander I, Eriksson SV, Forslund L, Wiman B. Fibrinolysis variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis Study in Stockholm. Circulation 1997; 95: 2380-6.
• 36 Cesari M, Rossi GP. Plasminogen activator inhibitor type 1 in ischemic cardiomyopathy. Arterioscler Thromb Vasc Biol 1999; 19: 1378-86.
• 37 Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Circulation 1995; 91: 284-90.
• 38 Durrington PN, Ishola M, Hunt L, Arrol S, Bhatnagar D. Apolipoproteins (a), A1, and B and parental history in men with early onset ischaemic heart disease. Lancet 1988; 1: 1070-3.
• 39 Sandkamp M, Funke H, Schulte H, Köhler E, Assmann G. Lipoprotein (a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 1990; 36: 20-3.
• 40 Parlavecchia M, Pancaldi A, Taramelli R, Valsania P, Galli L, Pozza G, Chierchia S, Ruotolo G. Evidence that apolipoprotein (a) phenotype is a risk factor for coronary artery disease in men <55 years of age. Am J Cardiol 1994; 74: 346-51.
• 41 Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PWF, Schaefer EJ, Castelli WP. Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 1996; 276: 544-8.
• 42 Abumiya T, Enjyoji K, Kokawa T, Kamikubo Y, Kato H. An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma. J Biochem 1995; 118: 178-82.
• 43 Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-9.
• 44 Ardissino D, Merlini PA, Ariëns R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997; 349: 769-71.
• 45 Tremoli E, Camera M, Toschi V, Colli S. Tissue factor in atherosclerosis. Atherosclerosis 1999; 144: 273-83.
• 46 Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Neri Serneri GG. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost 1998; 79: 495-9.
• 47 Soejima H, Ogawa H, Yasue H, Kaikita K, Nishiyama K, Misumi K, Takazoe K, Miyao Y, Yoshimura M, Kugiyama K, Nakamura S, Tsuji I, Kumeda K. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999; 99: 2908-13.
• 48 Sandset PM, Bendz B. Tissue factor pathway inhibitor: Clinical deficiency states. Thromb Haemost 1997; 78: 467-70.
• 49 Moor E, Hamsten A, Karpe F, Båvenholmn P, Blombäck M, Silveira A. Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age. Thromb Haemost 1994; 71: 707-12.
• 50 Abumiya T, Yamaguchi T, Terasaki T, Kokawa T, Kario K, Kato H. Decreased plasma tissue factor pathway inhibitor activity in ischemic stroke patients. Thromb Haemost 1995; 74: 1050-4.
• 51 Kokawa T, Enjyoji K, Kumeda K, Kamikubo Y, Harada-Shiba M, Koh H, Tsushima M, Yamamoto A, Kato H. Measurement of the free form of TFPI antigen in hyperlipidemia. Relationship between free and endothelial cell-associated forms of TFPI. Arterioscler Thromb Vasc Biol 1996; 16: 802-8.
• 52 Meade TW, Cooper J, Miller GJ, Howarth DJ, Stirling Y. Antithrombin III and arterial disease. Lancet 1991; 338: 850-1.
• 53 Thompson SG, Fechtrup C, Squire E, Heyse U, Breithardt G, van de Loo JC, Kienast J. Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris. Arterioscler Thromb Vasc Biol 1996; 16: 357-62.
• 54 Vaughan DE. The renin-angiotensin system and fibrinolysis. Am Heart J 1997; 79: 12A-6A.
• 55 Seed M, O’Connor B, Perombelon N, O’Donnell M, Reaveley D, Knight BL. The effect of nicotinic acid and acipimox on lipoprotein (a) concentration and turnover. Atherosclerosis 1993; 101: 61-8.
• 56 Takamiya O, Ishida F, Kodaira H, Kitano K. APC-resistance and MnI I genotype (Gln 506) of coagulation factor V are rare in Japanese population. Thromb Haemost 1995; 74: 996.